Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia
Improving Oral Chemotherapy Adherence in Maintenance for Adolescents and Adults With Acute Lymphoblastic Leukemia Using Text Messages
1 other identifier
interventional
38
1 country
1
Brief Summary
The purpose of this section is to learn how text message reminders might help with regularly taking chemotherapy medications for Adolescents and Adults with Acute Lymphoblastic leukemia (ALL).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 31, 2024
CompletedFirst Posted
Study publicly available on registry
June 6, 2024
CompletedStudy Start
First participant enrolled
December 15, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2027
Study Completion
Last participant's last visit for all outcomes
June 15, 2028
March 4, 2026
March 1, 2026
6 months
May 31, 2024
March 2, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To compare adherence to oral chemotherapy with mercaptopurine and methotrexate
To compare adherence to oral mercaptopurine and methotrexate during the first 84-day cycle of maintenance therapy for patients with ALL on pediatric-based regimens between those who receive the high intensity text message intervention and those who receive standard of care.
84 days
Secondary Outcomes (1)
To describe the relationship between oral chemotherapy adherence and patient factors
1 year
Other Outcomes (2)
To compare percentage of time during maintenance at goal absolute neutrophil count (ANC) and platelet count for patients
1 year
To compare clinical outcomes during and after maintenance therapy for AYA patients
1 year
Study Arms (2)
High Intensity
ACTIVE COMPARATORReceives high-intensity text messaging for 2 cycles of treatment
Low Intensity
ACTIVE COMPARATORReceives no texts for 1st cycle and low-intensity texts for 2nd cycle
Interventions
Eligibility Criteria
You may qualify if:
- Age of 15-39 years-old at the time of initial ALL diagnosis
- Diagnosed with ALL
- Currently receiving treatment with pediatric-based regimen that includes maintenance with mercaptopurine and methotrexate (e.g., CALGB 10403). Study participation begins with the start of maintenance, so enrollment occurs prior to the start of maintenance.
You may not qualify if:
- Patient or caregiver who would receive text message reminders does not have a cell phone that receives text messages
- Patient does not wish to participate
- Text messages will be crafted in the patient's preferred language for medical communication, so English fluency is not an enrollment requirement.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wendy Stock
University of Chicago
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 31, 2024
First Posted
June 6, 2024
Study Start (Estimated)
December 15, 2026
Primary Completion (Estimated)
June 15, 2027
Study Completion (Estimated)
June 15, 2028
Last Updated
March 4, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share
Study results including PHI such as dates, assigned study ID, and initials may be shared with researchers and their teams at other sites as part of required safety reporting notifications (e.g. serious events/unanticipated problems, or other reportable events). Final reports (no PHI) may also be shared. Names and medical record numbers will not be shared externally. Data will only be shared for analysis purposes.